In addition, the KRAS (G12V) and KRAS (G12D) mutations enhanced the infiltration of MDSCs in the TME by upregulating GM-CSF in PDAC and CRC, thereby leading to antitumour immune escape108,109. This evidence concerns the gene KRAS and colorectal carcinoma.